Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Agenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow

AGEN
Agenus to Report Fourth Quarter and Year End 2012 Financial Results on February 28, 2013; Conference Call to Follow

LEXINGTON, Mass., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) will release its fourth quarter and year ended December 31, 2012 financial results before the market opens on February 28, 2013.

Agenus executives will host a conference call at 11:00 a.m. Eastern Time that same day. To access the live call, dial 877.475.3568 (domestic) or 678.809.3092 (international); the access code is 14310694. The call will also be webcast and will be accessible from the company's website at www.agenusbio.com/webcast/. A replay will be available approximately two hours after the call through midnight Eastern Time on April 25, 2013. The replay number is 855.859.2056 (domestic) or 404.537.3406 (international), and the access code is 14310694. The replay will also be available on the company's website approximately two hours after the live call.

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 19 programs are in clinical development. For more information, please visit www.agenusbio.com.

The Agenus logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8187

CONTACT: Media and Investor Contact:
         Jonae R. Barnes
         Vice President
         Investor Relations and
         Corporate Communications
         jonae.barnes@agenusbio.com
         617-818-2985

company logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today